Julia Levy, Ph.D. Chair and Director. Dr. Levy served as Chair of the Board and Founder of QLT. Dr. Levy served in several key senior posts at QLT including Chief Scientific Officer and Vice President as well as President and CEO from 1995 to February 2002. Following her doctorate degree in immunology from the University of London, Dr. Levy was awarded an Industrial Professorship in the Department of Microbiology from the University of British Columbia and is the recipient of several honorary degrees. A fellow of the Royal Society of Canada and former President of the Canadian Federation of Biological Sciences, Dr. Levy has earned numerous awards and honors including an appointment as an Officer of the Order of Canada in 2001, the Female Entrepreneur of the Year for International Business in 1998, Pacific Canada Entrepreneur of the Year in 2000 and the Future of Vision Award from the Foundation Fighting Blindness in 2001. In 2002 she received the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. Along with Dr. Gustav Huber of Novartis, she was presented with the 2003 Helen Keller Prize for Innovation in Eye Care.
Richard Glickman, LLD. Director. Dr. Glickman was co-founder of Aspreva Pharmaceutical Corporation where he served as Chairman of the Board and Chief Executive Officer from 2002 to 2008. In 1990, Dr. Glickman co-founded Stressgen Biotechnologies Corporation, a biotechnology company, and served as its Chief Executive Officer until 2000. Dr. Glickman’s awards include being honoured with Canada’s Top 40 Under 40 and E&Y’s Entrepreneur of the Year Award. Dr. Glickman currently serves as a director of Cardiome Pharma Corp. and Medgenesis Therapeutix Inc. Dr. Glickman holds a B.Sc. in Microbiology and Immunology from McGill University.
Brenda Irwin, MBA Director. Ms. Irwin is a Partner, Venture Capital, Business Development Bank of Canada. Her 13 years of venture capital financing experience ranges from investments in private seed-stage companies to investments in publicly listed companies. Ms. Irwin has served on the boards of directors of 15 private and public Canadian life sciences and medical technology companies. Her honours include being awarded with B.C.’s Top 40 Under 40 Award. Ms. Irwin holds a BSc. in Human Biology and Biomedical Science, and a B.A. in English, from the University of Guelph. She also holds a Bed. from Queen’s University, and an MBA from the University of British Columbia.
Don Campbell Director. Mr. Campbell is the senior strategy advisor at Davis LLP providing non-legal advisory services to the firm's clients in connection with their business strategies, with a particular emphasis on strategies dealing with governments and governmental agencies in Canada and internationally. Prior to joining Davis, Mr. Campbell was Executive Vice-President of CAE Inc. He joined CAE in September 2000 and served as Group President of the Military Simulation and Training Division until June, 2006. Prior to his time at CAE, Mr. Campbell had a distinguished career with Canada's Department of Foreign Affairs and International Trade. As Assistant Deputy Minister, Mr. Campbell was deeply involved in the Canada-United States Free Trade Agreement and as Deputy Minister of International Trade he supervised the negotiation of the North America Free Trade Agreement (NAFTA). Mr. Campbell was formerly Deputy Foreign Minister (1997-2000), the Prime Minister's Personal Representative for G-8 Summits (1997-2000), Canada's Ambassador to Japan (1993-1997), Deputy Minister for International Trade (1989-1993), the Assistant Deputy Minister (United States) (1985-1989) and Canada's Ambassador to Korea (1984-1985). Mr. Campbell currently serves as a Director for Toyota Canada Inc., Canfor Pulp Holding Inc., Davie Yards Inc. and the Perimeter Institute.
Alistair Duncan, B.Sc., C.A. Director. See Management.
